Gene Review:
NBR1 - neighbor of BRCA1 gene 1
Homo sapiens
Synonyms:
1A1-3B, 1A13B, CA125, Cell migration-inducing gene 19 protein, IAI3B, ...
- Isolation of the murine Nbr1 gene adjacent to the murine Brca1 gene. Chambers, J.A., Solomon, E. Genomics (1996)
- Expression of BRCA1, NBR1 and NBR2 genes in human breast cancer cells. Dimitrov, S.D., Matousková, E., Forejt, J. Folia Biol. (Praha) (2001)
- CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Olivier, R.I., Lubsen-Brandsma, M.A., Verhoef, S., van Beurden, M. Gynecol. Oncol. (2006)
- Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Karlan, B.Y., Baldwin, R.L., Lopez-Luevanos, E., Raffel, L.J., Barbuto, D., Narod, S., Platt, L.D. Am. J. Obstet. Gynecol. (1999)
- Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Meeuwissen, P.A., Seynaeve, C., Brekelmans, C.T., Meijers-Heijboer, H.J., Klijn, J.G., Burger, C.W. Gynecol. Oncol. (2005)
- Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Phillips, K.A., Jenkins, M.A., Lindeman, G.J., McLachlan, S.A., McKinley, J.M., Weideman, P.C., Hopper, J.L., Friedlander, M.L. Clin. Genet. (2006)
- Outcome of five years of accelerated surveillance in patients at high risk for inherited breast/ovarian cancer: report of a phase II trial. Fries, M.H., Hailey, B.J., Flanagan, J., Licklider, D. Military medicine. (2004)
- Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. Paramasivam, S., Tripcony, L., Crandon, A., Quinn, M., Hammond, I., Marsden, D., Proietto, A., Davy, M., Carter, J., Nicklin, J., Perrin, L., Obermair, A. J. Clin. Oncol. (2005)
- The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Parker, P.A., Kudelka, A., Basen-Engquist, K., Kavanagh, J., de Moor, J., Cohen, L. Gynecol. Oncol. (2006)
- A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. Bast, R.C., Klug, T.L., St John, E., Jenison, E., Niloff, J.M., Lazarus, H., Berkowitz, R.S., Leavitt, T., Griffiths, C.T., Parker, L., Zurawski, V.R., Knapp, R.C. N. Engl. J. Med. (1983)
- Re: Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. Pisal, N., Sindos, M., Singer, A. J. Natl. Cancer Inst. (2003)
- Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma. Mann, W.J., Patsner, B., Cohen, H., Loesch, M. J. Natl. Cancer Inst. (1988)
- E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Auersperg, N., Pan, J., Grove, B.D., Peterson, T., Fisher, J., Maines-Bandiera, S., Somasiri, A., Roskelley, C.D. Proc. Natl. Acad. Sci. U.S.A. (1999)
- High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer. Barton, D.P., Blanchard, D.K., Michelini-Norris, B., Nicosia, S.V., Cavanagh, D., Djeu, J.Y. Blood (1993)
- Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Berchuck, A., Soisson, A.P., Clarke-Pearson, D.L., Soper, J.T., Boyer, C.M., Kinney, R.B., McCarty, K.S., Bast, R.C. Cancer Res. (1989)
- Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Davis, H.M., Zurawski, V.R., Bast, R.C., Klug, T.L. Cancer Res. (1986)
- Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? Gronlund, B., Høgdall, C., Hilden, J., Engelholm, S.A., Høgdall, E.V., Hansen, H.H. J. Clin. Oncol. (2004)
- Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. Rustin, G.J., Nelstrop, A.E., Crawford, M., Ledermann, J., Lambert, H.E., Coleman, R., Johnson, J., Evans, H., Brown, S., Oster, W. J. Clin. Oncol. (1997)
- Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Ferry, D.R., Smith, A., Malkhandi, J., Fyfe, D.W., deTakats, P.G., Anderson, D., Baker, J., Kerr, D.J. Clin. Cancer Res. (1996)
- Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Smith, T.M., Lee, M.K., Szabo, C.I., Jerome, N., McEuen, M., Taylor, M., Hood, L., King, M.C. Genome Res. (1996)
- The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. Brown, M.A., Xu, C.F., Nicolai, H., Griffiths, B., Chambers, J.A., Black, D., Solomon, E. Oncogene (1996)
- The kinase domain of titin controls muscle gene expression and protein turnover. Lange, S., Xiang, F., Yakovenko, A., Vihola, A., Hackman, P., Rostkova, E., Kristensen, J., Brandmeier, B., Franzen, G., Hedberg, B., Gunnarsson, L.G., Hughes, S.M., Marchand, S., Sejersen, T., Richard, I., Edström, L., Ehler, E., Udd, B., Gautel, M. Science (2005)
- Brca1 expression is regulated by a bidirectional promoter that is shared by the Nbr1 gene in mouse. Whitehouse, C., Chambers, J., Catteau, A., Solomon, E. Gene (2004)
- Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells. Marth, C., Zeimet, A.G., Widschwendter, M., Ludescher, C., Kaern, J., Tropé, C., Gastl, G., Daxenbichler, G., Dapunt, O. Cancer Res. (1997)
- Crystal structure of the PB1 domain of NBR1. Müller, S., Kursula, I., Zou, P., Wilmanns, M. FEBS Lett. (2006)
- CA 125: fundamental and clinical aspects. Verheijen, R.H., von Mensdorff-Pouilly, S., van Kamp, G.J., Kenemans, P. Semin. Cancer Biol. (1999)
- Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon. Marth, C., Fuith, L.C., Böck, G., Daxenbichler, G., Dapunt, O. Cancer Res. (1989)
- Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells: inhibition by glucocorticoids. Karlan, B.Y., Amin, W., Casper, S.E., Littlefield, B.A. Cancer Res. (1988)
- Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. Rustin, G.J., Gennings, J.N., Nelstrop, A.E., Covarrubias, H., Lambert, H.E., Bagshawe, K.D. J. Clin. Oncol. (1989)
- NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube. Whitehouse, C., Chambers, J., Howe, K., Cobourne, M., Sharpe, P., Solomon, E. Eur. J. Biochem. (2002)
- Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:psiBRCA1 recombination. Brown, M.A., Lo, L.J., Catteau, A., Xu, C.F., Lindeman, G.J., Hodgson, S., Solomon, E. Hum. Mutat. (2002)
- Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins. Lamark, T., Perander, M., Outzen, H., Kristiansen, K., Øvervatn, A., Michaelsen, E., Bjørkøy, G., Johansen, T. J. Biol. Chem. (2003)
- Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Oei, A.L., Massuger, L.F., Bulten, J., Ligtenberg, M.J., Hoogerbrugge, N., de Hullu, J.A. Br. J. Cancer (2006)
- Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. Schwartz, M.D., Kaufman, E., Peshkin, B.N., Isaacs, C., Hughes, C., DeMarco, T., Finch, C., Lerman, C. J. Clin. Oncol. (2003)